Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Riyue BaoStefani SprangerKyle HernandezYuanyuan ZhaPeter PytelJason John LukeThomas F GajewskiSamuel L VolchenboumSusan L CohnAmi V DesaiPublished in: Journal for immunotherapy of cancer (2022)
Our results indicate that tumors from children with high-risk neuroblastoma harboring a strong T cell-inflamed signature have a more favorable clinical outcome, and neoantigen load is a prognosis predictor, independent of T cell inflammation. Strategies to target SOX11 and other signaling pathways associated with non-T cell-inflamed tumors should be pursued as potential immune-potentiating interventions.